Content Team, Author at Trogenix

Scottish biotech debuts with ‘Trojan horse’ platform for cancer

Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate targeting an aggressive type of brain…

Content Team In News

Trogenix unveils revolutionary platform to transform cancer treatment through precision viral immunotherapy.

Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the University of Edinburgh to commercialise its breakthrough Synthetic Super-Enhancer platform, Odysseus,…

Content Team In News

World-leading experts in gene therapy and brain cancer treatment convene in Edinburgh to advance Trogenix’s novel glioblastoma programme.

Trogenix recently hosted a landmark workshop at The Royal College of Surgeons in Edinburgh, uniting pioneering experts in neurosurgery, gene therapy, and oncology to advance…

Content Team In News

Trogenix awarded Innovate UK grant to advance innovative viral immunotherapy platform for treating cancers with significant unmet medical need.

Grant will accelerate development and evaluate Trogenix’s SSE technology in liver hepatocellular carcinoma and colorectal cancer liver metastases Edinburgh, UK, January 2024 - Trogenix Ltd…

Cookie	Duration	Description
__cf_bm	1 hour	This cookie, set by Cloudflare, is used to support Cloudflare Bot Management.
_cfuvid	session	Calendly sets this cookie to track users across sessions to optimize user experience by maintaining session consistency and providing personalized services
cookielawinfo-checkbox-analytics	1 year	Set by the GDPR Cookie Consent plugin, this cookie records the user consent for the cookies in the "Analytics" category.
cookielawinfo-checkbox-functional	1 year	The GDPR Cookie Consent plugin sets the cookie to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	1 year	Set by the GDPR Cookie Consent plugin, this cookie records the user consent for the cookies in the "Necessary" category.
CookieLawInfoConsent	1 year	CookieYes sets this cookie to record the default button state of the corresponding category and the status of CCPA. It works only in coordination with the primary cookie.
rc::a	never	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
rc::c	session	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
viewed_cookie_policy	1 year	The GDPR Cookie Consent plugin sets the cookie to store whether or not the user has consented to use cookies. It does not store any personal data.
wpEmojiSettingsSupports	session	WordPress sets this cookie when a user interacts with emojis on a WordPress site. It helps determine if the user's browser can display emojis properly.

Cookie	Duration	Description
_ga	1 year 1 month 4 days	Google Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors.
_ga_*	1 year 1 month 4 days	Google Analytics sets this cookie to store and count page views.

Content Team

Scottish biotech debuts with ‘Trojan horse’ platform for cancer

Trogenix unveils revolutionary platform to transform cancer treatment through precision viral immunotherapy.

World-leading experts in gene therapy and brain cancer treatment convene in Edinburgh to advance Trogenix’s novel glioblastoma programme.

Trogenix awarded Innovate UK grant to advance innovative viral immunotherapy platform for treating cancers with significant unmet medical need.

Trogenix Ltd 4‑5 Little France Drive IRR North Building BioQuarter Edinburgh UK EH16 4UU

Trogenix Ltd
4‑5 Little France Drive
IRR North Building
BioQuarter
Edinburgh
UK
EH16 4UU